Ascendis Pharma (ASND) Misses Q3 EPS by 72c
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Join SI Premium – FREE
Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR1.00), EUR0.72 worse than the analyst estimate of (EUR0.28). Revenue for the quarter came in at EUR213.63 million versus the consensus estimate of EUR213.17 million.
For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Baird Downgrades Teradyne (TER) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
